Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Dr. Pollack on the Future Treatment Landscape for Sarcoma

April 8th 2017

Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the future treatment paradigm of soft tissue sarcoma.

A Call for Molecular Profiling in Uterine Carcinosarcoma

March 22nd 2017

Douglas Levine, MD, discusses a recent study in uterine carcinosarcoma and early steps toward developing therapeutic regimens.

Chemotherapy Approach Avoids Amputation in Sarcoma Patients

March 22nd 2017

John E. Mullinax, MD, discusses isolated limb infusion as a limb salvage strategy for locally advanced extremity sarcoma.

Dr. Wilky on Ongoing Trial of Pembrolizumab and Axitinib in Sarcoma

March 21st 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses the status of a phase II trial investigating concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in patients with advanced alveolar soft part sarcoma and other soft tissue sarcomas.

Dr. Blay Discusses the Treatment Landscape of Sarcoma

March 21st 2017

Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses the treatment landscape of sarcoma.

Dr. Kasper on Imatinib Versus Sorafenib in Sarcoma

March 18th 2017

Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses imatinib (Gleevac) versus sorafenib (Nexavar) as treatments for patients with sarcoma.

Dr. Albertsmeier on Radiotherapy Improving the Local Control of Sarcoma

March 17th 2017

Markus Albertsmeier, MD, surgeon, Ludwig Maximilian University of Munich, discusses radiotherapy improving the local control for patients with sarcoma.

Dr. Gordon on Next Steps With Immunotherapy Research in Osteosarcoma

March 15th 2017

Nancy B. Gordon, MD, assistant professor, Department of Pediatrics, The University of Texas MD Anderson Center, discusses next steps for immunotherapy research in the field of osteosarcoma.

Dr. Grignani Discusses the Safety Profile of Trabectedin in Sarcoma

March 10th 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the safety profile of trabectedin (Yondelis) in the treatment of sarcoma.

Dr. Gordon on Immunotherapy Research in Osteosarcoma

March 3rd 2017

Nancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses current immunotherapy research being conducted in the field of osteosarcoma.

Novel Compound GPX-150 Shows Promise in Soft Tissue Sarcoma

February 23rd 2017

Brian Van Tine, MD, PhD, discusses the potential of the investigational compound 5-imino-13-deoxydoxorubicin (GPX-150) in metastatic and nonresectable soft tissue sarcoma.

Dr. Albertsmeier on Radiation Therapy for Soft Tissue Sarcoma

February 21st 2017

Marcus Albertsmeier, MD, surgeon at Ludwig Maximilian University of Munich, discusses the effect of radiation therapy on local recurrence and overall survival for patients with soft tissue sarcoma.

Dr. Wilky on Pembrolizumab Plus Axitinib in Sarcoma

February 18th 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses a phase II trial exploring concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in advanced alveolar soft part sarcoma and other soft tissue sarcomas.

Dr. Gordon on Immunotherapy Treatment for Osteosarcoma

February 17th 2017

Nancy B. Gordon, MD, assistant professor, department of pediatrics, The University of Texas MD Anderson Center, discusses immunotherapy treatments for osteosarcoma.

EBRT Lowers Local Recurrence Risk in Soft Tissue Sarcoma

February 13th 2017

Markus Albertsmeier, MD, discusses the results of the meta-analysis and the implications going forward for the treatment of patients with soft tissue sarcoma.

Dr. Blay on the Heterogeneity of Soft Tissue Sarcoma

February 7th 2017

Jean-Yves Blay, MD, PhD, professor of Medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses the heterogeneity of soft tissue sarcoma.

PD-1 Blockade Potential Comes to Light in Sarcoma Subtypes

February 6th 2017

An immunohistochemistry analysis of a large patient population demonstrated that several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings presented at the 2017 European Cancer Congress in Amsterdam.

Dr. Grignani on the Role of Trabectedin in Sarcoma

February 4th 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses some of the data seen thus far with trabectedin as a treatment for patients with sarcoma.

Dr. Pollack on the Potential Impact of Radiomics on the Sarcoma Treatment Landscape

February 3rd 2017

Seth M. Pollack, MD, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the potential impact that radiomics could have on the treatment landscape of sarcoma.

Dr. Catton on Omitting Radiation Therapy in Sarcoma

January 25th 2017

Charles Catton, MD, professor, Department of Radiation Oncology, University of Toronto, discusses the notion of omitting radiation therapy in the treatment of patients with extremity sarcoma.